Tempus AI Raises FY2026 Sales Guidance to $1.595B-$1.605B

Tempus AI (NASDAQ: TEM) has raised its full-year 2026 sales guidance, signaling robust demand for its artificial intelligence-driven healthcare solutions. The company updated its revenue outlook to a range of $1.595 billion to $1.605 billion, an increase from the previous guidance of $1.590 billion to $1.600 billion. This revision places the midpoint of the new guidance above the consensus market estimate of $1.593 billion, indicating that management expects stronger-than-anticipated performance for the fiscal year.

The upward revision underscores the accelerating adoption of Tempus’s data and analytics platform across clinical and commercial settings. By lifting the top end of its guidance range by $50 million, the company highlights improved visibility into its near-term revenue streams. The new outlook suggests that recent product enhancements or expanded partnerships are driving higher engagement with healthcare providers and pharmaceutical clients.

Updated Financial Outlook

The following table details the change in Tempus AI’s fiscal year 2026 sales guidance compared to prior expectations and market estimates.

Metric	Previous Guidance	New Guidance	Market Estimate
Low End	$1.590 billion	$1.595 billion	-
High End	$1.600 billion	$1.605 billion	-
Midpoint	$1.595 billion	$1.600 billion	$1.593 billion

What the Numbers Show

The decision to raise both the floor and ceiling of the sales range demonstrates a broad-based improvement in business fundamentals rather than a narrow adjustment at the margins. With the new midpoint of $1.600 billion surpassing the $1.593 billion analyst estimate, Tempus AI is positioning itself as a leader in the AI-healthcare intersection. Investors should note that this guidance increase reflects operational momentum, suggesting that the company’s strategic initiatives are effectively converting into tangible revenue growth ahead of schedule.

Tempus AI, Inc. has announced the national launch of its OneOme pharmacogenomics (PGx) testing solution, designed to deliver advanced genetic insights that optimize medication safety, dosing, and toxicity risk assessment. This strategic expansion enhances the company's precision medicine capabilities by addressing how a patient's body processes treatments.

The introduction of the OneOme solution follows Tempus AI's acquisition of OneOme in November 2025. By fully integrating these capabilities, Tempus AI aims to bridge the critical gap between genomic tumor profiling and the practical application of treatment data.

Precision Medicine Portfolio Expansion

The integration of OneOme allows Tempus AI to offer a more comprehensive suite of diagnostic tools. The pharmacogenomics testing provides clinicians with actionable data to tailor treatments based on individual genetic profiles.